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The 27th annual meeting of the Society for Immunotherapy of Cancer (SITC) was held on October 26–28, 2012 in
North Bethesda, Maryland and the highlights of the meeting are summarized. The topics covered at this meeting
included advances in cancer treatment using adoptive cell therapy (ACT), oncolytic viruses, dendritic cells (DCs),
immune check point modulators and combination therapies. Advances in immune editing of cancer, immune
modulation by cancer and the tumor microenvironment were also discussed as were advances in single cell
analysis and the manufacture and potency testing of tumor infiltrating lymphocytes (TIL).
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The immune system plays an important role in cancer
progression and cancer therapy. In many ways the im-
mune system of cancer patients is suppressed and the
tumors actively evade immune surveillance. T cells, es-
pecially those within tumors, are impaired functionally
and tumors induce T and NK cell apoptosis. The tumors
also create a unique microenvironment that promotes
tumor growth and blocks the anti-tumor activities of
T cells.
In a keynote address, Robert Schreiber (Washington
University, Saint Louis, MI) described that cancer cells
go through 3 phases of immune editing; elimination,
equilibrium and escape [1]. In the elimination phase
newly emerging cancer cells are recognized and elimi-
nated. In the equilibrium phase the cancer cells are rec-
ognized but can no longer be eliminated and in the
escape phase the tumor cells are no longer recognized.
Immune editing is dependent on CD8+ cells, CD4+ cells
and the recognition of target antigens. Mutated antigens
are often involved with immune editing of tumor cells.* Correspondence: dstroncek@cc.nih.gov
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reproduction in any medium, provided the orThe expression of mutated antigens allows tumors to be
recognized by the immune system. The loss of these mu-
tated antigens allows the tumors to escape the immune
system.
As described by Theresa Whiteside (University of
Pittsburgh, Pittsburg, PA) during the Richard Smalley
Memorial Award Lecture, tumors induce many changes
in host immune response that contribute to immune es-
cape. These changes include the induction of T cell
apoptosis and expansion of TREG cells. Many cancers in-
duce reductions in the quantities of circulating T cells
which likely influences clinical outcomes. The reduction
in the number of T cells and proliferation of TREG cells
is mediated in part by tumor-derived exosomes (TEX)
whose levels are increased in the sera of cancer patients
[2]. These exosomes express a number of cell surface re-
ceptors and ligands including FAS ligand and exosomes
isolated from the sera of cancer patients have been
shown to induce FAS mediated apoptosis of T cells.
Tumor derived exosomes also promote TREG cell prolif-
eration. They also interact with monocytes to yield
myeloid-derived suppressive cells (MDSC).
As pointed out by David H. Munn (Georgia Health
Sciences University, Augusta, GA), the indoleamine 2,3-
dioxygenase (IDO) pathway is also likely a majoral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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IDO is a natural factor that is a counter immune regula-
tor in that it is induced by inflammation but it is im-
munosuppressive [3]. It regulates both the innate and
adaptive immune responses. IDO is expressed by a wide
range of cancer cells and increased levels are associated
with poor clinical outcomes. IDO is also expressed by
dendritic cells (DCs) in tumor draining lymph nodes
and FOXO3 induces IDO expression in DCs [4].
The down-regulation of NF-κβ activity may also con-
tribute to immune suppression in tumor-bearing hosts.
NF-κβ activity is down-regulated in T cells from hosts
with tumors. The reduced NF-κβ activation results in re-
duced T cell survival, reduced Th1 and Th17 differenti-
ation and increased TREG cell differentiation. Cesar
Evaristo and colleagues (University of Chicago, Chicago,
IL, USA) have found that the forced overexpression of
NF-κβ in mice resulted in fewer TREG cells and increased
frequency of interferon-γ producing T cells and en-
hanced rejection of B16 melanoma cells that had been
engineered to express the model SIYRYYGL (SIY)
antigen [5].
Patients with chronic hepatitis C virus (HCV) infec-
tion often develop hepatocellular carcinoma and recent
data suggests that the NK cell function is abnormal in
patients with chronic HCV infection. Maria Libera
Ascierto and colleagues (Clinical Center, NIH, Bethesda,
MD, USA) have been evaluating the role of NK cells in
the outcome of patients with HCV infections. The tran-
scriptome of peripheral blood NK cells from chronically
viremic treatment-naïve HCV patients was compared
with patients who spontaneously achieved virus eradica-
tion and healthy subjects. NK cells from patients who
spontaneously eradicated HCV upregulated genes in-
volved with activation of NK cell function and cells from
chronically viremic patients had enhanced expression of
genes involved with interferon signaling and IL-15
production.
Tumor microenvironment
The tumor microenvironment is increasingly been iden-
tified as having a critical role in tumor cell growth and
rejection. Michael Kershaw and colleagues (Peter
MacCallum Cancer Center, Melbourne, Australia) have
found differences in microenvironment due to tumor lo-
cation which affect response to therapy [6]. Immuno-
therapy consisting of antibodies directed to death
receptor 5 (DR5), CD40 and CD137 (4-1BB) works less
well in orthotopically implanted renal cell tumors than
subcutaneously implanted tumors. The number of im-
mune cells in the renal and subcutaneous tumor micro-
environments was similar, but their characteristics
differed. More M2 macrophage and Th2 cell genes were
expressed by cells in the microenvironment of kidneytumors than in subcutaneous tumors. The vasculature
also differed among the tumors as more blood vessels
were present in kidney tumors.
While some critical aspects of the microenvironment
have yet to be completely understood, it is clear that the
presence of lymphocytes is an important factor. Lymph
node-like structures, identified in melanoma microenvir-
onment, are associated with improved responses to im-
munotherapy. James Mule and colleagues (Moffitt Cancer
Center, Tampa, FL, USA) studied a 12-chemokine gene
expression signature on arrays of 14,492 solid tumors
across 24 different tissue types [7]. The twelve genes were
CCL2, CCL3, CCL4, CCL5, CCL8, CCL18, CCL19,
CCL21, CXCL6, CXCL10, CXCL11 and CXCL13. Among
melanoma samples, those with a signature demonstrating
up-regulation of all 12 genes exhibited unique lymph
node-like structures. The expression of these 12 genes
was also found to be associated with better overall sur-
vival. The expression of these 12-cytokine genes may be
useful in the selection of patients most suitable for
immunotherapy.
Targeting immune suppression
Antibodies to PD-1 and PD-L1
A mechanism of immune escape involves the PD-1 and
PD-L1 pathway. PD-1 is up-regulated by T cells chronic-
ally activated by antigen stimulation, and its engagement
by PD-L1 on tumor cells down-regulates the ability of
activated T cells to produce cytokines, proliferate and
kill target cells. PD-L1 is expressed by many tumors.
Antibody blockage of the PD-1/PD-L1 pathway can in-
duce tumor regression in several tumor models. Recent
studies by Xiufen Chen and Justin Kline (University of
Chicago, Chicago, IL, USA) suggest that blockade of the
PD-1/PD-L1 pathway may not only result in the re-
activation of effector T cells, but may also prevent the
induction of TREG cells.
The PD-1/PD-L1 pathway appears to play a key role in
immune suppression in multiple myeloma. Myeloma
cells express high levels of PD-L1 and myeloma-
infiltrating T cells express increased levels of PD-1. Tyce
Kearl, Weiqing Bing and Bryon Johnson (Medical
College of Wisconsin, Milwaukee, W, USA) used a
murine model of multiple myeloma to show that
anti-PDL1 can enhance the clearance of myeloma by
tumor-experienced T cells when it was combined with
lymphodepleting irradiation. Both host CD4+ and CD8+
cells were required to improve killing of myeloma cells.
Interestingly, anti-PD-L1 and lymphodepletion did not
improve survival in two other solid tumor models.
The potential of PD-1/PD-L1 blockade has led to the
clinical development of antibodies capable of blocking
this pathway. One of the potential limitations of anti-PD-
L1 therapy is that the antibody may reduce lymphocyte
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T cells. The cells are cleared by an Fc dependent mech-
anism, antibody-dependent cell-mediated cytotoxicity
(ADCC). Bryan Irving (Genentech, South San Francisco,
CA, USA) reported the results of testing an anti-PD-L1
with Fc domain that has been altered to reduce ADCC
clearance and lymphopenia. Preclinical studies using
tumor bearing mice have found that the modified anti-
PD-L1 was effective as a single agent and in combin-
ation with tumor-targeted therapies.
Another recently developed antibody capable of block-
ing this pathway is MEDI4736 which is also specific for
PD-L1. Ross Stewart and collaborators (MedImmune,
Cambridge, UK and Astra Zeneca Waltham, MA)
reported that this antibody only activates T cells in the
context of an activated T cell receptor (TCR) signal. This
antibody has been shown to inhibit tumor growth in ani-
mal models.
Anti-CTLA-4
Antibody blockade of the CTLA-4 pathway is another
mechanism that is useful in overcoming cancer-induced
T cell suppression. Anti-CTLA-4 has been found to in-
duce durable remissions in some patients with melan-
oma. Luana Calabro and collaborators (University
Hospital of Siena, Siena, Italy and MedImmune,
Gaithersburg, MD, USA) reported that one such anti-
body, tremelimumab, has beneficial effects when used in
combination with platinum-based chemotherapy to treat
malignant mesothelioma. Among the 29 patients treated
in a phase II clinical trial, two patients had partial clin-
ical responses and four had prolonged stable disease
and one patient remained alive 28 months after therapy.
It appears that one of the mechanisms by which anti-
CLTA-4 enhances T cell responses to tumors is by epitope
spreading. Pia Kvistborg and colleagues (Netherlands
Cancer Institute, Amsterdam, Netherlands) used a high-
throughput methodology to study cytotoxic T cell epitopes
before and after the administration of the anti-CTLA-4
antibody ipilimumab, in 26 patients with melanoma. They
found significant increases in the number of melanoma-
associated epitopes recognized by CD8+ T cells after
ipilimumab but the overall magnitude of melanoma-
specific T cell responses was not changed.
MicroRNA
Some investigators are studying microRNA (miR) as a
method to reverse cancer-associated immune suppres-
sion. Amy Heimberger and colleagues (University of
Texas, MD Anderson Cancer Center, Houston, TX,
USA) have found that the expression of miR-124, a
modulator of the T cell transcription factor Signal Trans-
ducer and Activator Transcription 3 (STAT3), is down-
regulated in gliomas. The up-regulation of miR-124 inglioma cells increased T cell proliferation and inhibition
of FOXP3+ TREG cells. The administration of miR-124 in
murine models of glioma resulted in anti-glioma effects
suggesting that miR-124 may be a novel immune-
activating agent for glioma therapy.
IL-15 therapy
IL-15 has recently become available for use in early
phase clinical trials as an alternative to IL-2. IL-15 is a
member of the γ-chain family of cytokines and it in-
creases the proliferation, survival and function of T and
NK cells [8]. Alternative forms of IL-15 are being devel-
oped and tested. When natural IL-15 is released in vivo
it is not stable, but circulating IL-15 exists naturally in
association with the IL-15 receptor alpha (IL-15Rα) to
form a stable IL-15/IL-15Rα heterodimer [9]. Further
studies by Cristina Bergamaschi and colleagues (National
Laboratory for Cancer Research, Frederick, MD, USA)
have compared the pharmacokinetics of single chain
IL-15 and IL-15/IL-15Rα heterodimer in mice and rhesus
macaques and found that, following intravenous adminis-
tration, the half-life of IL-15/IL-15Rα is about 6 times lon-
ger than IL-15 single chain. The intravascular levels of the
heterodimer are higher and more stable when it is given
subcutaneously than intravenously; when the heterodimer
is given as a subcutaneous injection the plasma levels of
IL-15 persist for 72 hours. In rhesus macaque, five sub-
cutaneous injections of the heterodimer repeated every
3 days resulted in significant expansion of γδ, CD8+ T and
NK cells in the peripheral blood.
Adoptive cell transfer (ACT) therapy
The clinical application of ACT continues to grow and
clinical response rates continue to improve [10]. As
pointed out by Laszlo Radvanyi (MD Anderson Cancer
Center, Houston, TX, USA) the use of the classic tumor
infiltrating lymphocyte (TIL) immunotherapy is growing
and many new TIL-based regimens are being developed.
Nine centers are currently using TIL to treat patients
with metastatic melanoma and it is estimated that over
300 patients have been treated. In these independent tri-
als, TIL therapy has reproducibly been shown to result
in objective clinical responses with response rates
reported in up to 70% of treated melanoma patients
[11]. The administration of non-myeloablative leuko-
reductive therapy prior to TIL infusion has improved
clinical outcomes by increasing the availability of the
serum cytokine IL-7 and IL-15 levels, opening T cell
niches and eliminating TREG cells and MDSC. A variety
of leukoreduction protocols have been used including
cyclophosphamide alone, cyclophosphamide plus fludara-
bine and cyclophosphamide/ fludarabine/total body irradi-
ation (TBI) [11,12]. For instance, Cassian Yee (MD
Anderson Cancer Center, Houston, TX, USA) reported
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mide alone followed by the infusion of peripheral blood
mononuclear cell-derived, antigen specific CD8+ CTL
clones in melanoma patients has resulted in the long-term
persistence of T cells and, that differentiated effector
T cells could revert to a central memory phenotype
in vivo following adoptive transfer [12].
While TIL therapy was already known to be a promis-
ing therapy, several road blocks had hindered its broader
use and commercialization. Robert Keefe (Lonza,
Walkersville, MD, USA) pointed out that, from a cell man-
ufacturer’s view, the traditional manufacturing protocols
for TIL production were: 1) long, requiring 5 to 7 weeks
to complete, 2) labor intensive, 3) used large quantities of
reagents and supplies and 4) required peripheral blood
leukocytes (PBL) cells for the rapid expansion process.
Additionally, TIL potency biomarkers were not yet identi-
fied. However, as highlighted by multiple speakers, sub-
stantial, progress has been made in all of these areas and
has thus garnered increased commercial interest.
The long duration of TIL production is due, in part, to
the practice of selecting tumor-reactive TIL for rapid ex-
pansion. Several approaches can shorten TIL production.
One approach has been to forgo the selection of tumor
reactive T cells entirely and begin TIL rapid expansion
immediately after they are isolated. The cells produced
by this method are known as “young TIL” [13]. Another
approach involves the selection of tumor-specific T cells
expressing activation markers. Alena Gros and col-
leagues (Surgery Branch, NCI, Bethesda, MD, USA) have
found that among fresh TIL isolated from melanoma
tumor digests, the subpopulation of tumor-specific T cells
isolated with MART-1 peptide-MHC tetramers expressed
higher levels of three negative co-stimulatory molecules
that are expressed by chronically stimulated T cells: PD-1,
LAG-3 and TIM-3 and a positive co-stimulatory molecule,
4-1BB. They also isolated and expanded fresh TIL subsets
and found that tumor reactivity was preferential in
effector-derived cells expressing PD-1, LAG-3, TIM-3 and
4-1BB. This suggests that these markers could be used to
enrich TIL for melanoma-reactive T cells.
TIL rapid expansion has been further improved by
changing the type of flasks used for TIL expansion. At
some centers, TIL are now being expanded in gas-
permeable flasks rather than traditional T-flasks and
bags. TIL can be grown at a greater density in gas-
permeable flasks which results in the use of less media
[14]. TIL rapid expansion in gas-permeable flasks rather
than T-flask and bags requires approximately 5- to 8-fold
less media and media supplements including cytokines
and AB serum. This results in a significant reduction in
the cost of TIL production.
An additional difficulty with the typical methods used
to expand TIL is that irradiated pooled allogeneicperipheral blood leukocytes (PBL) collected from healthy
subjects are used as feeder cells to stimulate TIL rapid
expansion. It would be desirable to have an alternate off-
the-shelf, widely available product for TIL expansion.
Artificial antigen presenting cells are being evaluated as
a substitute for allogeneic PBL feeder cells for TIL rapid
expansion. Paramagnetic beads coated with anti-CD3
and anti-CD28 can be used to stimulate the rapid, but
low level expansion of TIL, however, these beads also re-
sult in a preferential increase in CD4+ cells in the final
product. Daniel Powell and colleagues (University of
Pennsylvania, Philadelphia, PA, USA) have been testing
off-the-shelf cell artificial antigen presenting cells (APCs)
as feeder cells for the rapid expansion of TIL [15]. They
are using K562 cells that are genetically engineered to
express Fc receptors and costimulatory ligands, such as
4-1BBL. The engineered artificial APCs are then loaded
with anti-CD3/anti-CD28 antibodies allowing them to
function as APCs. These artificial APCs have been used
to expand TIL from melanoma and ovarian cancer. The
degree of expansion and cell characteristic were similar
to those expanded with allogeneic PBL but at lower TIL:
APC ratios, meaning fewer feeder cells are required. In
addition, these artificial APCs maintained a favorable
CD8/CD4 ratio and FOXP3+ CD4+ cell frequency. Arti-
ficial APCs have the capacity to expand both “young”
TIL and TIL selected from tumor-reactive cytotoxic T
cells. Compared to allogeneic feeder cells, artificial APCs
represent a more standardized “off-the-shelf” cellular
platform for TIL expansion.
As discussed by multiple presenters during the meet-
ing, several TIL characteristics that are associated with
better clinical outcomes and likely a more potent prod-
uct have now been identified. The administration of TIL
products with longer telomeres, increased expression of
the co-stimulator molecule CD27 and expression of
CD45RO+ and CD28bright are associated with better clin-
ical outcomes [11]. New work is aimed at identifying the
functional attributes of persisting TIL [16]. The infusion
of greater number of TIL and longer intravascular per-
sistence have also been associated with improved clinical
outcome [17]. Faster reconstitution of CD4+, Foxp3+
cells after TIL therapy has been correlated with worse
clinical outcomes [18]. In addition, TIL products with a
more differentiated effector phenotype of the CD8+
population and a higher frequency of CD8+ T cells co-
expressing the negative costimulation molecule B- and
T-lymphocyte attenuator (BTLA) are associated with
better clinical outcomes [17].
Since results emerging from TIL therapy trials suggest
that clinical outcome is dependent in part on the num-
ber of TIL infused, efforts are being made to increase
the quantity of TIL produced from each patient. Yong
Qing Li and Cassian Yee (Fred Hutchinson Cancer
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Cancer Center, Houston, TX, USA) have found that the
expansion of CTLs in culture can be increased by the
depletion of TREG cells with anti-CD25 and treatment
with IL-21. Furthermore, exposure to IL-21 during
in vitro priming led to the generation of helper-
independent CTL with a central memory phenotype
(CD45RO+, CD28hi, CD62Lhi+, IL-2+), a strategy which
Yee has now implemented in first-in-man clinical studies
[19,20]. Interestingly, as pointed out by Pamela S.
Ohashi (Ontario Cancer Institute/University Health
Network, Toronto, Canada), the presence of NK cells in
TIL have been associated with reduced proliferation and
altered cytokine production of CD8+ T cells. In addition,
NK cells have an immune regulatory function [21]; they
have been found to limit CD8+ T mediated toxicity, ra-
tionalizing their depletion from TIL products for infu-
sion. Together, findings such as these highlight the great
advancements being made in immunology and technol-
ogy which makes it more feasible than ever to efficiently
generate autologous tumor-reactive TIL products of high
quality and quantity for use in adoptive immunotherapy
of cancer.
Genetically engineered T cells
In order to improve ACT therapy, T cells are being gen-
etically engineered in a number of ways. Investigators
lead by Steven A. Rosenberg (Surgery Branch, NCI,
Bethesda, MD, USA) have engineered TIL to express
IL-12 in order to improve their effectiveness [22]. Con-
ferring the ability of tumor antigen-specific T cells to
produce IL-12 greatly improves their function in a var-
iety of pre-clinical studies [23,24]. Since IL-12 can cause
systemic toxicity, they have been attempting to focus
IL-12 production and prevent systemic toxicity by in-
cluding a nuclear factor of activated T cells (NFAT)
transcription factor in addition to IL-12 in the vector
used to engineer TIL. This results in T cells that tran-
scribe IL-12 only when the TCR is triggered. Autolo-
gous T cells are also being engineered to express high
affinity TCRs. One of the challenges of this approach is
to target antigens that have enough specificity to the
tumor so that cancer regresses without causing off tar-
get toxicity and complications. Some clinical trials have
used T cells engineered to express high affinity TCRs
that recognize MART-1 and NY-ESO [25,26].
The preliminary results of early phase clinical trials of
T cells that have been engineered to express chimeric
antigen receptors (CAR) have been very promising and
research in this area is growing rapidly. Three centers
have reported the results of anti-CD19 CAR T cell clin-
ical trials treating B cell lymphomas and leukemias and
while the result at all three centers have been promising,
there were several differences among the trials [27-29].The vectors used in the trials differed: two different scFv
portions of anti-CD19 were used, two different co-
stimulatory molecules, CD28 and 4-1BB, were used and
both retro and lentiviral vectors were used. Leukocyte
depletion is important for the success of this therapy
[29] and the pre-treatment leukoreduction protocols also
differed among the three centers.
While the results of anti-CD19 CAR T cell therapy
have been encouraging, the therapy itself has been asso-
ciated with some toxicity including cytokine storm,
tumor lysis syndrome and depletion of CD19+ B cells
[27,28]. As a result, Michel Sadelain and colleagues
(Memorial Sloan-Kettering Cancer Center, New York,
NY, USA) are attempting to improve the safety of CAR
T cell therapy. To limit off target toxicity, tumor sensing
T cell are being developed [30,31]. One approach is to en-
gineer T cells so that they recognize two antigens, thereby
being less likely to cause off target cytotoxicity. Another
approach to limit toxicity is to use transiently expressed
RNA vectors rather than permanently expressed lentiviral
or retroviral vectors. Using murine models, Nathan Singh
and colleagues (University of Pennsylvania and Children’s
Hospital of Philadelphia, Philadelphia, PA, USA) have
found that multiple treatments with RNA CD19 CAR T
cells were as effective in treating acute lymphocytic
leukemia (ALL) as one treatment with lentivirus CD19
CAR T and multiple RNA GD2 CAR T cell doses were
nearly as effective in treating neuroblastoma as a single
dose of lentivirus GD2 CAR T cells.
Improving ACT therapy by using less
differentiated T cells
Several ACT clinical trials have found that prolonged
persistence of adoptively transferred CD8+ T cells is as-
sociated with better clinical outcomes. Nicholas Restifo
(Surgery Branch, NCI, Bethesda, MD, USA) reported
that investigators are attempting to use CD8+ T cells
with a younger or more stem-like phenotype which have
a longer in vivo life-span and greater proliferative poten-
tial for clinical therapy [32]. Preclinical studies have
shown that naïve (TN), stem memory (TSCM) and central
memory (TCM) CD8
+ T cells have better engraftment
and anti-tumor efficacy than more differentiated effector
memory (TEM) and effector (TEFF) CD8+ T cells [33].
Christopher Klebanoff and colleagues (Surgery Branch,
NCI, Bethesda, MD, USA) have found that memory
(TMEM) CD8+T cells can induce the differentiation of
TN. They found that when TMEM were present, activated
TN differentiated more rapidly than activated TN alone
[34]. This precocious differentiation was TCR-ligation
dependent and required cell-to-cell contact. Further
studies found that it was blocked by disruption of FasL-
Fas signaling and was reproduced by exogenous FasL tri-
mers in absence of TMEM cells. These studies suggest
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cells from adoptive cellular therapies is necessary to pre-
vent the corruption of the full potential of less differenti-
ated anti-tumor T cells.
Stephen Forman and colleagues (City of Hope National
Medical Center, Duarte, CA, USA) are attempting to
improve CAR anti-CD19 therapy by using as starting
material peripheral blood TCM rather than a mixed per-
ipheral blood T cell population. TCM have a unique
capacity for self-renewal, proliferation, persistence and
an ability to differentiate into effector T cells. The
CD8+CD45RO+CD62L+TCM cells were obtained by de-
pleting peripheral blood leukocytes of those cells ex-
pressing CD4, CD14 and CD45RA and then selecting
cells expressing CD8 and CD62L. The isolated cells are
then stimulated with anti-CD3/ anti-CD28 beads, trans-
duced with a vector containing an anti-CD19 CAR and
expanded with IL-2 and IL-15 for 3 to 6 weeks. Under a
phase I/II clinical trial these autologous cells are being
given to patients with non-Hodgkin lymphoma two days
after receiving an autologous hematopoietic stem cell
transplant.
Philip D. Greenberg and colleagues (University of
Washington, Seattle, WA, USA) are using a novel com-
bination of cytokines to maintain a young phenotype
during T cell culture and expansion. The cytokine IL-21
arrests T cell differentiation and IL-15 promotes TCM cell
differentiation [35,36]. Expansion of T cells with IL-21,
IL-7 and IL-15 produces cells that retain a central-
memory-like phenotype (CD62L+, CCR7+, CD28+) [20,37].
Another approach to obtaining less differentiated cells
for adoptive cell transfer appears to be blockage of T cell
glycolysis. Madhusudhanan Sukumar and colleagues
(Surgery Branch, NCI, Bethesda, MD, USA) have found
that cellular metabolism influences T cell fate and func-
tion. They found that TN cells which relay on fatty acid
oxidation as a primary source for ATP generation,
shifted to a glucose metabolism following antigen stimu-
lation and effector differentiation. Blockade of glycolysis
during T cell priming by 2-deoxyglucose (2-DG)
prevented differentiation and the treatment of tumor-
bearing mice with 2-DG treated T cells resulted in in-
creased tumor-infiltration, cytokine release and tumor
regression than control cells.
Dendritic cell therapy
DC therapy is showing promising results in several dif-
ferent types of cancer. Brian Czerniecki and colleagues
(University of Pennsylvania, Philadelphia, PA, USA) have
given DC vaccines to patients with HER-2/neu over-
expressing ductal carcinoma in situ (DCIS) prior to sur-
gical resection [38]. The DCs were pulsed with six MHC
class II peptides and two HLA-A2.1 binding class I bind-
ing peptides and were given at four weekly intervals.Post immunization T cell responses were documented
using ELISPOT in 85% of the 27 patients against MHC
class I peptides and in 88% to MHC class II peptides.
The vaccine appeared to have been of some clinical
benefit in five patients that displayed no evidence of re-
sidual DCIS and HER-2 expression was undetectable in
11 patients. The post vaccine surgical specimens showed
increased infiltration of CD4+ T cells, CD8+ T cells and
CD20+ B cells.
DC vaccines have also been used to treat patients with
metastatic melanoma and the availability of an autolo-
gous melanoma cell line. Robert Dillman and colleagues
(Hoag Institute for Research and Education, Hoag Hos-
pital, Newport Beach, CA, USA) treated 42 patients ei-
ther with irradiated autologous proliferating tumor cells
or DCs pulsed with these tumor cells. The tumor cells
or DCs were given once weekly for 3 weeks and then
monthly for 5 months. The survival was significantly
better in patients given the DCs with a 2-year survival of
72% compared to 31%.
Sipuleucel-T is an autologous DC-like immunotherapy
approved for the treatment of castrate resistant prostate
cancer. Recent studies have shown that this therapy af-
fects the immune cell infiltrate in the prostate cancer
microenvironment. In a phase II clinical trial sipulecel-T
has been given to 42 patients prior to radical prostatec-
tomy and Lawrence Fong and colleagues (Helen Diller
Family Comprehensive Cancer Center, USCF, San
Francisco, CA, USA) have investigated the prostate bi-
opsies of these patients. They found that sipuleucel-T
increased infiltration of T and B cells in the microenvir-
onment. They also documented systemic T and B cell
activation.
Approximately 20% of all cancers are associated with
viral infections. The oncogenic virus human papilloma
virus (HPV) causes cervical cancer, vulvar cancer, anal
cancer and head and neck cancer. Cornelis Melief and
colleagues (Leiden University Medical Center, Leiden,
Netherlands) have developed a long peptide vaccine to
treat HPV associated cancers. Both Th1 and Th2 CD4+
cell immunity to HPV is directed to HPV type 16
(HPV16) proteins E2, E6, E7 and L1 and CD8+ cell im-
munity is directed to E6. A peptide vaccine was devel-
oped to avoid the high costs associated with the
production of DCs. Since proteins are inefficient at CD8+
cytotoxic T cell induction and short peptides do not pro-
duce adequate CD8 memory response due to lack of
CD4+ helper cell induction, long peptides which are
processed and presented by DCs were used in the vac-
cine. The clinical grade HPV16 SLP vaccine consists of
13 long peptides covering the entire length of the
HPV16 E6 and E7 proteins. A phase I clinical trial in-
volving patients with advanced cervical cancer found
that the vaccine was safe and induced T cell IFN-γ
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VIN2 pre-malignant lesions resulted in objective re-
sponses in >50% of patients after 12 months and 9 of
the patients had complete and durable regression after
24 months. The strength of vaccine-induced HPV-16
T cell specific responses correlated with significant
clinical response [41,42]. The vaccine is currently be-
ing tested in combination with chemotherapy.
Data from Pawel Kalinski, Hideho Okada and col-
leagues (University of Pittsburgh, Pittsburgh, PA, USA)
showed that DCs maturing in different conditions in-
duce different forms of immune responses. Data from
Kalinski lab demonstrate that IL-12 produced by DC
vaccines is an important factor in the induction of GrB+
effector CD8+ T cells (CTLs) expressing high levels of
peripheral-homing receptors, CCR5 and CXCR3 [43]. A
recently completed phase I/II clinical trial [44], demon-
strated that the level of IL-12 production by DC vaccines
is a predictive factor of delayed time to progression in
patients with high grade recurrent gliomas (GBM+AA)
treated with DC vaccines and poly-ICLC. Disease
stabilization of 12 months or longer was observed in 9
of 22 accrued patients. Preclinical data, showing strong
synergy between TLR3 ligands, IFNα, and COX2 inhibi-
tors in the induction of the chemokine ligands for CCR5
and CXCR3 in tumor tissues [45], led to recent imple-
mentation of additional clinical studies testing the com-
bined use of DC vaccines and tumor-conditioning
factors in colorectal cancer.
Oncolytic viruses
Vaccinia viruses infect and lyse some tumors. Recent
clinical trials have found these oncolytic viruses to be
safe and in some cases they have demonstrated tumor
selectivity. Vaccinia infects most mammalian cell types
and causes minor illness in humans. Boris Minev and
collaborators (Genelux Corporation, San Diego, CA,
USA and the University of California San Diego, La Jolla,
CA, USA) have investigated the interactions of oncolytic
viruses with the host immune system. Analysis of the
mononuclear cell subset tropism of several oncolytic
vaccinia virus constructs found that they preferentially
infected monocytes and activated T cells, but were much
less likely to infect B cells, NK cells and resting T cells.
However, the viral amplification and cytotoxicity were
greater in control cancer cells than in the mononuclear
cells. Oncolytic vaccinia is now being used to treat pa-
tients with chronic myelomonocytic leukemia (CMML)
in an early phase clinical trial.
Vaccinia has been engineered to express GM-CSF in
order to modulate the tumor microenvironment and en-
hance anti-tumor immunity and has been used as an
anti-tumor vaccine [46,47]. Another vaccinia-based ther-
apy being tested in clinical trials is Fowlpox-GM-CSFTRICOM. Edmund Lattime and colleagues (Cancer
Center of New Jersey, New Brunswick, NJ, USA) are
testing fowlpox virus engineered to express GM-CSF
plus TRICOM, a triad of costimulatory molecules,
consisting of LFA-3, ICAM and B7.1. TRICOM provides
T cell costimulation in the context of tumor antigen
presentation. The recombinant fowlpox vector is being
tested in patients with bladder cancer in a phase I clin-
ical trial. PanVac is another vaccinia virus vaccine ex-
pressing TRICOM and two pancreatic cancer antigens,
carcinoembryonic antigen (CEA) and mucin 1 (MUC-1).
PanVac is being given intratumorally to patients with
pancreatic cancer. PanVac has been given to 11 patients
with locally advanced disease and although 10 patients
in the trial remained metastasis-free, they all died of
local disease progression.
Sung Yong Lee and colleagues (Johns Hopkins Medical
Institutions, Baltimore, MD, USA) are investigating the
use of vaccinia virus containing a vector expressing the
chimeric protein calreticulin (CRT) linked to the human
papilloma virus protein E7 (HPV-E7) (CRT/E7-VV) as a
treatment for cervical cancer. E7 is a tumor antigen and
CRT improves antigen presentation by MHC class I
molecules and amplifies T cell responses. This virus is
being tested for the treatment of cervical cancer using a
murine model. The vaccine is given with cisplatin
chemotherapy in order to change the tumor microenvir-
onment by causing tumor lysis which increases antigen
uptake by DCs. The authors reported that the combin-
ation of the vaccine and chemotherapy induced sys-
temic anti-tumor effects and increase the number of E7
specific CD8+ T cells in the blood.
Vesicular stomatitis virus (VSV) is also being used in
cancer immune therapy [48]. As shown by Richard Vile
(Mayo Clinic, Rochester, MN, USA), VSV engineered to
express interferon-β is being tested in a phase I clinical
trial in patients with hepatocellular carcinoma. The VSV
was administered as an intratumoral injection. Studies of
tumor bearing mice have found that the mechanism by
which VSV induces tumor lysis involves the induction of
strong innate immune response when injected into tu-
mors which likely is responsible for killing both infected
and non-infected tumor cells. VSV is also being used to
encode tumor associated antigens in order to prime
strong anti-tumor T cell responses. In addition, melan-
oma cDNA libraries expressed in VSV can be used to
identify tumor-associated antigens [49].
Bacteria as cancer vaccines
Bacteria are also being used for cancer vaccines. Listeria
monocytogenes has been engineered to express antigens
and used to treat cancers [50]. Listeria preferentially in-
fects monocytes and generates a strong innate immune
response. ADXS11-001 (ADXS-HPV) LM-LLO is a live
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a HPV-16-E7 fusion protein. This immunotherapy is
designed to target HPV transformed cells and is being
evaluated by Robert Petit (Advaxis, Inc, Princeton, NJ,
USA) and Partha Basu (Chittaranjan National Cancer
Institute, Kolkata, India) for the treatment of cervical
cancer. Animal models have shown that ADXS-HPV in-
creases the level of circulating T cells and reduces the
levels of TREG cells and MDSCs breaking immune toler-
ance. ADXS11-001 has been used in a phase II clinical
trial of 110 patients with recurrent and refractory cer-
vical cancer that had been treated with chemotherapy or
radiotherapy. The patients received ADXS11-001 alone
or ADXS11-001 plus cisplatin chemotherapy. Some pa-
tients experienced complete responses and partial re-
sponses, but no improvement in responses were noted
in patients that received cisplatin chemotherapy in
addition to ADXS11-001.
Combining immunotherapy and targeted therapy
for melanoma
Antoni Ribas (University of California Los Angeles, CA,
USA) reported that traditional cancer chemotherapy or
novel targeted therapies are being tested in combination
to improve the effects of tumor immunotherapies. Sev-
eral agents have been used to overcome these problems
including a proteasome inhibitor (bortezomib) which
sensitizes NK cells, a Bcl-2 inhibitor (ABT-737) which
sensitizes T cells by making cancer cells sensitive to
granzyme B induced apoptosis [51] and the HDAC in-
hibitor (LAQ824) which improves antigen presentation
by tumor cells and enhances the function of T cells [52].
Another agent which sensitizes T cells has become avail-
able; the BRAF inhibitor vemurafenib or PLX4032. Ini-
tial studies of vemurafenib have been promising.
Clinically, vemurafenib has been found to increase the
quantity of T cell infiltrates in regressing melanomas.
Studies of pmel-1 murine melanoma model have found
that when given with ACT, vemurafenib increases im-
mune cell function and possibly modulates the tumor
microenvironment. Specifically vemurafenib paradoxic-
ally increased MAPK signaling, in vivo cytotoxic activity,
and intratumoral cytokine secretion by adoptively trans-
ferred cells [53].
Many cancers have RAS mitogen-activated protein
kinase (MAPK) oncogene mutations that lead to tumor
immune evasion in part due to immune escape. One
such mutation is the prevalent BRAF V600 mutation in
melanoma. Recently, it has been discovered that the in-
hibition of BRAF increases the activity of immunother-
apies. Antoni Ribas and colleagues demonstrated that in
mouse models, BRAF inhibitors increase the in vivo
cytotoxic activity and intratumoral cytokine secretion
by adoptively transferred cells, without altering theirexpansion, distribution, or tumor accumulation. More-
over, a BRAF inhibitor, vemurafenib (PLX4032), is effect-
ive in treating patients with advanced melanoma [54].
The tyrosine kinase inhibitor imatinib was originally
used to treat chronic myelogenous leukemia and Robert
de Mateo and colleagues (Memorial Sloan Kettering
Cancer Center, New York, NY, USA) have shown
imatinib to have antitumor activity in the treatment of
gastrointestinal stromal cell tumors (GIST) with muta-
tions in KIT, BRAF and PDGFRα [55]. A clinical trial in-
volving 694 patients with metastatic GIST found that
imatinib resulted in partial responses or stable disease in
about 80% of patients and median survival was almost
5 years [56]. In a second clinical trial, following surgical
resection of GIST, 713 patients were randomized to re-
ceive either imatinib or no additional therapy. Disease
recurrence and progression was delayed in patients
treated with Imatinib, but it did not result in improved
long-term disease free survival. Robert de Mateo and
colleagues have also reported that the quantity of T cells
in tumors post-imatinib therapy increased and the CD8/
TREG ratio improved in tumor samples from these stud-
ies. In addition, tumor associated macrophages (TAM)
are likely involved with the responses of GIST to
imatinib. TAM in GIST are predominantly inflammatory
(M1), which is atypical. The number of TAM decreased
in patients sensitive to imatinib but develop a type 2
phenotype post treatment. In contrast, the number of
TAM increase and retain a type M1 phenotype in pa-
tients resistant to imatinib [57].
Laurence Zitvogel (Institute Gustave Roussy, Paris,
France) reported that imatinib induces NK-mediated
tumor control in mice by acting on c-kit in DCs to pro-
mote NK and DC cell cross talk [58]. The number of
NK cells and T cells in GIST is greater than in other sar-
comas. These NK cells and T cells are activated and pro-
duce Th1 cytokines. Imatinib treatment is associated
with increased infiltration of GIST with NK cells and it
also increases the secretion of IFN-γ by NK cells in
blood and tumors. The infiltration of GIST by NK cells
is predictive of response to imatinib as is the activation
of circulating NK cells [59]. The molecular characteris-
tics of NK cells are important in the response of GIST
to imatinib. NK cells with different NKp30 alternate spli-
cing isoforms vary in their production of IFN-γ and IL-12
and GIST patients with the NKp30c isoform don’t benefit
from imatinib [60]. Serum biomarkers of imatinib respon-
siveness have been investigated and a target of NKp30, sol-
uble B7-H6, has been found to be effective when used in
combination with soluble MICA/B. In these studies, in-
creased levels of sB7-H6 and decreased levels of sMIC
were associated with poor prognosis.
Cetuximab is an antibody specific for epidermal
growth factor receptor (EGFR), which when used in
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duces clinical responses in 15% to 20% of patients with
head and neck cancer (HNC). Hyun-Bae Jie and col-
leagues (University of Pittsburgh Cancer Institute,
Pittsburgh, PA, USA) found that a possible explanation of
the limited response to this therapy may be related to
FOXP3+ TREG cells. The numbers of circulating and
intratumoral FOXP3+ TREG cells are increased in patients
with HNC tumors. After cetuximab treatment their num-
bers increased further. Furthermore, patients with greater
FOXP3+ TREG cell levels were less likely to respond to
cetuximab treatment.
Radiotherapy to enhance immunotherapy
Radiation therapy is reported to be able to convert the
tumor into an in situ vaccine by inducing tumor cell
death and a pro-inflammatory microenvironment. The
fact that this is a rare event suggests that radiotherapy
usually has an immunosuppressive effect. Studies by
Claire Vanpouille-Box and colleagues (NYU School of
Medicine, New York, NY, USA) have found that radio-
therapy causes immune suppression mediated by
transforming growth factor β (TGFβ). They found that
tumor-bearing mice treated with irradiation and a TGFβ
neutralizing antibody have fewer lung metastases than
mice treated with irradiation alone.
Single cell high throughput technologies
An important aspect of cancer immunotherapy is mea-
suring the immune response. Several advances have been
made in high throughput single cell analysis. As shown
by Alessandra Cesano (Nodality, South San Francisco,
CA, USA) a new approach to evaluate immune cells
known as the Single Cell Network Profile (SCNP) has
been developed. SCNP is a multiparametric flow
cytometry-based analysis that simultaneously measures,
at the single-cell level, both extracellular surface markers
and changes in intracellular signaling proteins in re-
sponse to extracellular modulators. This approach allows
for simultaneous functional measurements from mul-
tiple cell subpopulations without the need for prior cell
separation [61,62].
Another approach to evaluate immune cells is single
cell mass cytometry which is a multiparametric approach
that combines single cell analysis with mass spectrom-
etry. As discussed by Gary Nolan (Stanford School of
Medicine, Stanford, CA, USA), cells are first labeled with
antibodies conjugated with elemental isotopes, nebulized
to free ions with high temperature (7500K) and then an-
alyzed with mass cytometer. This approach allows the
analysis of over 45 different parameters at the single cell
level. Analysis of cells from cancer patients could be
used to find common meta-clusters, surface markers or
stem markers that can be different within and acrosspatients (pre-post treatment or recurrent forms of the
same cancer) [63,64].
Janet Siebert and collaborators (CytoAnalytics, Denver,
CO, USA and the Robert W. Franz Cancer Center,
Providence Cancer Center, Portland, OR, USA) have
used another high throughput approach to identify bio-
markers associated with longevity in melanoma patients
treated with the anti-CTLA-4 antibody ipilimumab. The
patients’ peripheral blood mononuclear cells were tested
before and after treatment with a 12-parameter flow cy-
tometry staining panel to delineate memory and effector
T cell subsets and a 10-parameter panel to delineate
TREG cell subsets. The memory/effector cell panel identi-
fied 32 phenotypes associated with “long-lived” patients
all of which were CD4+ cell phenotypes. In addition, the
“long-lived” patients were more likely to have a large
post therapy increase in early activated memory CD4+
T cells.
Clinical immunotherapy guidelines for the
treatment of melanoma
Howard Kaufman (Rush University, Chicago, IL, USA)
reported that SITC has been developing Clinical Im-
munotherapy Guidelines (CIG) and the first guidelines
are directed toward the treatment of melanoma. These
guidelines have been drafted and have been posted on
SITC web site and are open for comment. Future guide-
lines will address immunotherapy of genital-urinary tract
malignancies and hematological malignancies.
FDA update
Raj K. Puri, [US Food and Drug Administration (FDA),
Center for Biologics Evaluation and Research (CBER),
Bethesda, MD, USA], indicated that the FDA has re-
cently posted several new guidelines on their website
that are of interest to the SITC community. The new
guidelines include: Guidance for the Industry: Clinical
Considerations for Therapeutic Cancer Vaccines; Draft
In Vitro Companion Diagnostic Guidance; and Draft
Guidance for Industry: Codevelopment of two or more
Unmarketed Investigational Drugs for Use in Combin-
ation. The FDA Office of Cellular, Tissue and Gene
Therapies (OCTGT) also has some useful tools available
on the FDA website including the OCTGT Learning
Webinar series and References for the Regulatory
Process of the Office of Cellular, Tissue and Gene Ther-
apies (OCTGT). The FDA also has a new office of
Hematology and Oncology Products.
Conclusions
Immunotherapy of cancer continues to grow. The suc-
cess of TIL therapy is being documented at several cen-
ters and TIL production is becoming simpler and less
expensive. Anti-CD19 CAR T cell therapy continues to
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while new CAR therapies are being developed. T cells used
in ACT are being engineered to express high affinity TCRs
and IL-12. Methods to produce T cells with stem cell char-
acteristics are being developed for use in ACT in order to
improve the survival and proliferation adoptively trans-
ferred T cells. Several DC therapies have proven to reliably
induce peripheral blood T cell responses and T cell and B
cell infiltration into the tumor microenvironment. Addi-
tional antibodies capable of PD-1/PD-L1 and CTLA-4
pathway blockade are being developed. Initial studies of
immunotherapy combinations with targeted therapies
have been promising, as have vaccines making use of
oncolytic viruses, Listeria monocytogenes and mRNA.
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